Compare IH & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | ONCY |
|---|---|---|
| Founded | 1996 | 1998 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 106.1M |
| IPO Year | 2020 | 1999 |
| Metric | IH | ONCY |
|---|---|---|
| Price | $2.19 | $0.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 9.3K | ★ 645.1K |
| Earning Date | 12-19-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $123,215,612.00 | N/A |
| Revenue This Year | $39.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.55 | $0.33 |
| 52 Week High | $3.60 | $1.51 |
| Indicator | IH | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 45.03 |
| Support Level | $2.15 | $0.94 |
| Resistance Level | $2.40 | $1.00 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 21.44 | 26.16 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.